PacifiCorp to Pay $575 Million in Wildfire Settlement With U.S. Government 
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
OpenAI Targets $600B Compute Spend as IPO Valuation Could Reach $1 Trillion 
JPMorgan Closes Trump Accounts as $5 Billion Lawsuit Moves to New York 
Honeywell Reconsiders $2.4 Billion Johnson Matthey Catalyst Technologies Acquisition 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
Citigroup Private Bank Appoints Chad Reddy as West Market Executive in North America 
Microsoft Gaming Leadership Overhaul: Phil Spencer Retires, Asha Sharma Named New Xbox CEO 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Meta Platforms Cuts Equity Awards Again Amid Massive AI Investment Push 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
Geneva, Switzerland and Boston, MA - May 8, 2018- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will release its first quarter 2018 financial results on the morning of Wednesday, May 16, 2018. ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, on May 16, 2018 to discuss these financial results and provide a corporate update.
Investors may participate by dialing (844) 419-1772 for U.S. callers and (213) 660-0921 for international callers, and referring to conference ID 5663506. A webcast of the conference call can be accessed under the "Investors" section of ObsEva's website www.obseva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Marion Janic
RooneyPartners LLC
[email protected]
212-223-4017
Company Contact:
CEO Office contact
Shauna Dillon
[email protected]
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
[email protected]
Office 857-972-9347
Mobile 781-366-5726
Attachment
